35 related articles for article (PubMed ID: 1358582)
1. Phosphonate prodrugs: an overview and recent advances.
Heidel KM; Dowd CS
Future Med Chem; 2019 Jul; 11(13):1625-1643. PubMed ID: 31469328
[TBL] [Abstract][Full Text] [Related]
2. Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir.
Laho T; Clarke JD; Dzierlenga AL; Li H; Klein DM; Goedken M; Micuda S; Cherrington NJ
Biochem Pharmacol; 2016 Sep; 115():144-51. PubMed ID: 27381944
[TBL] [Abstract][Full Text] [Related]
3. High-Density Lipoproteins: Nature's Multifunctional Nanoparticles.
Kuai R; Li D; Chen YE; Moon JJ; Schwendeman A
ACS Nano; 2016 Mar; 10(3):3015-41. PubMed ID: 26889958
[TBL] [Abstract][Full Text] [Related]
4. Na⁺/H⁺ exchanger regulatory factor 3 is critical for multidrug resistance protein 4-mediated drug efflux in the kidney.
Park J; Kwak JO; Riederer B; Seidler U; Cole SP; Lee HJ; Lee MG
J Am Soc Nephrol; 2014 Apr; 25(4):726-36. PubMed ID: 24436471
[TBL] [Abstract][Full Text] [Related]
5. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy.
Leggas M; Adachi M; Scheffer GL; Sun D; Wielinga P; Du G; Mercer KE; Zhuang Y; Panetta JC; Johnston B; Scheper RJ; Stewart CF; Schuetz JD
Mol Cell Biol; 2004 Sep; 24(17):7612-21. PubMed ID: 15314169
[TBL] [Abstract][Full Text] [Related]
6. Cryopreservation enables long-term storage of 9-(2-phosphonylmethoxyethyl)adenine prodrug-loaded reconstituted lactosylated high-density lipoprotein.
de Vrueh RL; van Berkel TJ; Bijsterbosch MK
Pharm Res; 2001 Mar; 18(3):403-7. PubMed ID: 11442284
[No Abstract] [Full Text] [Related]
7. Carrier-mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to parenchymal liver cells: a novel therapeutic approach for hepatitis B.
de Vrueh RL; Rump ET; van De Bilt E; van Veghel R; Balzarini J; Biessen EA; van Berkel TJ; Bijsterbosch MK
Antimicrob Agents Chemother; 2000 Mar; 44(3):477-83. PubMed ID: 10681306
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of a lipophilic prodrug of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and its incorporation into a hepatocyte-specific lipidic carrier.
de Vrueh RL; Rump ET; Sliedregt LA; Biessen EA; van Berkel TJ; Bijsterbosch MK
Pharm Res; 1999 Aug; 16(8):1179-85. PubMed ID: 10468017
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.
Cundy KC
Clin Pharmacokinet; 1999 Feb; 36(2):127-43. PubMed ID: 10092959
[TBL] [Abstract][Full Text] [Related]
10. Disposition of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine.
Bijsterbosch MK; Smeijsters LJ; van Berkel TJ
Antimicrob Agents Chemother; 1998 May; 42(5):1146-50. PubMed ID: 9593142
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.
Cundy KC; Sueoka C; Lynch GR; Griffin L; Lee WA; Shaw JP
Antimicrob Agents Chemother; 1998 Mar; 42(3):687-90. PubMed ID: 9517952
[TBL] [Abstract][Full Text] [Related]
12. Antimalarial and toxic effects of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine in Plasmodium berghei-infected mice.
Smeijsters LJ; Nieuwenhuijs H; Hermsen RC; Dorrestein GM; Franssen FF; Overdulve JP
Antimicrob Agents Chemother; 1996 Jul; 40(7):1584-8. PubMed ID: 8807044
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients.
Cundy KC; Barditch-Crovo P; Walker RE; Collier AC; Ebeling D; Toole J; Jaffe HS
Antimicrob Agents Chemother; 1995 Nov; 39(11):2401-5. PubMed ID: 8585716
[TBL] [Abstract][Full Text] [Related]
14. Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo.
Neyts J; Stals F; Bruggeman C; De Clercq E
Eur J Clin Microbiol Infect Dis; 1993 Jun; 12(6):437-46. PubMed ID: 8395382
[TBL] [Abstract][Full Text] [Related]
15. Oral, subcutaneous, and intramuscular bioavailabilities of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl) adenine in cynomolgus monkeys.
Cundy KC; Shaw JP; Lee WA
Antimicrob Agents Chemother; 1994 Feb; 38(2):365-8. PubMed ID: 8192467
[TBL] [Abstract][Full Text] [Related]
16. Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys.
Cundy KC; Fishback JA; Shaw JP; Lee ML; Soike KF; Visor GC; Lee WA
Pharm Res; 1994 Jun; 11(6):839-43. PubMed ID: 7937523
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenine.
Naesens L; Balzarini J; De Clercq E
Drug Metab Dispos; 1992; 20(5):747-52. PubMed ID: 1358582
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine.
Naesens L; Balzarini J; Bischofberger N; De Clercq E
Antimicrob Agents Chemother; 1996 Jan; 40(1):22-8. PubMed ID: 8787873
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
